NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency affects one in six men over 50 years1; representing a significant burden," said Gabriel Baertschi, CEO Grünenthal. "With the completion of this deal, we can now work to bring this meaningful treatment to ...
Aachen, Germany (ots) - - Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovative non-opioid investigational medicine. - The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. - Globally, more than 300 million patients ...
Aachen, Germany (ots) - - Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. - NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. - Grünenthal has invested over € 2 billion in successful M&A ...
